Inventor · disambiguated record
Isil Altintas
Also filed as: ALTINTAS ISIL
16 granted patents·17 pending applications·98 citations·filing 2011–2025
93Inventor score
Top patents by PatentIndex Score
33 records- 0198US11440966B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Sep 13, 2022·12 cites·21 claims
- 0298US11084882B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2020·Granted Aug 10, 2021·8 cites·11 claims
- 0396US11091557B2Methods of producing multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2017·Granted Aug 17, 2021·10 cites·20 claims
- 0495US12077596B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Sep 3, 2024·2 cites·20 claims
- 0595US11939388B2Multispecific antibodies against CD40 and CD137GENMAB AS·Filed 2021·Granted Mar 26, 2024·2 cites·13 claims
- 0694US10407501B2Humanized or chimeric CD3 antibodiesGENMAB AS·Filed 2015·Granted Sep 10, 2019·15 cites·19 claims
- 0793US10544220B2Bispecific antibodies against CD3 and CD20GENMAB AS·Filed 2016·Granted Jan 28, 2020·18 cites·12 claims
- 0892US11613575B2Humanized or chimeric CD3 antibodiesGENMAB AS·Filed 2019·Granted Mar 28, 2023·4 cites·18 claims
- 0992US11359015B2Humanized or chimeric CD3 antibodiesGENMAB AS·Filed 2016·Granted Jun 14, 2022·6 cites·24 claims
- 1087US12421319B2Binding agents that bind OX40 (CD134) and method of use thereof to treat diseaseBioNTech SE·Filed 2023·Granted Sep 23, 2025·0 cites·11 claims
- 1186US11459395B2Binding agents binding to PD-L1 and CD137 and use thereofGENMAB AS·Filed 2021·Granted Oct 4, 2022·1 cites·19 claims
- 1283US9339554B2Tunable, biodegradable linker molecules for transient conjugation of components in drug delivery systems, and drug delivery systems prepared therewithRIJCKEN CRISTIANNE JOHANNA FERDINAND·Filed 2011·Granted May 17, 2016·19 cites·14 claims
- 1383US2023374131A1Humanized or chimeric cd3 antibodiesGENMAB AS·Filed 2023·Application pending·0 cites
- 1482US10968280B2Binding agents binding to PD-L1 and CD137 and use thereofGENMAB AS·Filed 2020·Granted Apr 6, 2021·1 cites·12 claims
- 1582US2023089969A1Multispecific antibodies against cd40 and cd137GENMAB AS·Filed 2022·Application pending·0 cites
- 1677US2023027394A1Humanized or chimeric cd3 antibodiesGENMAB AS·Filed 2022·Application pending·0 cites
- 1777US2023087745A1Binding agents binding to pd-l1 and cd137 and use thereofGENMAB AS·Filed 2022·Application pending·0 cites
- 1877US2022389101A1Humanized or chimeric cd3 antibodiesGENMAB AS·Filed 2022·Application pending·0 cites
- 1977US2022380464A1Humanized or chimeric cd3 antibodiesGENMAB AS·Filed 2022·Application pending·0 cites
- 2074US11814411B2Nucleic acid molecules encoding binding agents to CD40 and 4-1BB (CD137)BioNTech SE·Filed 2021·Granted Nov 14, 2023·0 cites·14 claims
- 2174US2024317861A1Antibodies against pd-l1GENMAB AS·Filed 2023·Application pending·0 cites
- 2273US2023212301A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 2372US10927181B2Agonistic tumor necrosis factor (TNF) receptor binding agentsBioNTech SE·Filed 2019·Granted Feb 23, 2021·0 cites·20 claims
- 2472US2023109496A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB BV·Filed 2022·Application pending·0 cites
- 2571US2025289900A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 2671US2025289899A1Antibodies capable of binding to cd27, variants thereof and uses thereofGENMAB AS·Filed 2025·Application pending·0 cites
- 2759US2020199231A1Bispecific antibodies against cd3 and cd20GENMAB AS·Filed 2019·Application pending·0 cites
- 2859US2025325643A1Binding agents capable of binding to cd27 in combination therapyGENMAB AS·Filed 2023·Application pending·0 cites
- 2956US10457735B2Methods of inducing T cell activation by administering an antibody comprising CD40 and 4-1BB (CD137) binding domainsBIONTECH AG·Filed 2016·Granted Oct 29, 2019·0 cites·3 claims
- 3053US2020239579A1Antibodies against pd-l1GENMAB AS·Filed 2018·Application pending·0 cites
- 3151US2023087164A1Antibodies for use in therapyGENMAB AS·Filed 2021·Application pending·0 cites
- 3251US2023310599A1Antibody therapyGENMAB AS·Filed 2021·Application pending·0 cites
- 3350US2021369842A1Antibody formulationGENMAB AS·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Isil Altintas files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →